Stereotaxis, Inc. Stock

Equities

STXS

US85916J4094

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 11:35:51 2024-05-23 am EDT 5-day change 1st Jan Change
2.04 USD -2.39% Intraday chart for Stereotaxis, Inc. -2.15% +16.86%
Sales 2024 * 29.5M Sales 2025 * 44.25M Capitalization 172M
Net income 2024 * -19M Net income 2025 * -16M EV / Sales 2024 * 5.82 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 3.88 x
P/E ratio 2024 *
-8.89 x
P/E ratio 2025 *
-11.1 x
Employees 122
Yield 2024 *
-
Yield 2025 *
-
Free-Float 84.22%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.39%
1 week-2.15%
Current month-12.98%
1 month-20.12%
3 months-32.95%
6 months+21.01%
Current year+16.86%
More quotes
1 week
2.00
Extreme 2
2.17
1 month
2.00
Extreme 2
2.61
Current year
1.72
Extreme 1.7199
3.29
1 year
1.33
Extreme 1.33
3.29
3 years
1.33
Extreme 1.33
10.30
5 years
1.33
Extreme 1.33
10.30
10 years
0.47
Extreme 0.47
10.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 16-09-28
Director of Finance/CFO 55 02-12-31
General Counsel - 20-12-31
Members of the board TitleAgeSince
Director/Board Member 78 05-04-30
Chief Executive Officer 57 16-09-28
Director/Board Member 68 17-02-02
More insiders
Date Price Change Volume
24-05-23 2.045 -2.15% 171 320
24-05-22 2.09 -0.95% 376,561
24-05-21 2.11 +0.96% 236,391
24-05-20 2.09 -0.48% 210,186
24-05-17 2.1 +0.48% 316,585

Delayed Quote Nyse, May 23, 2024 at 11:22 am EDT

More quotes
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.09 USD
Average target price
4.5 USD
Spread / Average Target
+115.31%
Consensus